Posted by Michael Wonder on 29 Jun 2024
Tubulis receives FDA fast track designation for antibody drug conjugate candidate TUB-040 in platinum-resistant ovarian cancer
27 June 2024 - Designation for TUB-040 in platinum-resistant ovarian cancer is based on preclinical data in a range of models, demonstrating superior biophysical properties with effective and durable responses.
Tubulis announced today that the US FDA has granted fast track designation to its lead antibody-drug conjugate TUB-040 for the treatment of patients with platinum-resistant ovarian cancer.
